普拉德马根Zamikeracel:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.
Molecular diagnosis & therapy
|August 28, 2025
概括
普拉德马基因扎米克拉塞尔 (ZEVASKYNTM) 提供了一种新型的基因疗法,用于治疗衰退性表皮溶解. 通过恢复 COL7A1 基因功能,
科学领域:
- 复原医学
- 基因治疗
- 皮肤病学
背景情况:
- 这是一种严重的遗传性疾病,其特征是皮肤脆弱和慢性伤口.
- RDEB 源于 COL7A1 基因的突变,导致功能性 VII 型原体的缺乏.
- 目前治疗RDEB的重点是伤口护理和疼痛管理,解决潜在的遗传原因的选择有限.
研究的目的:
- 概述prademagene zamikeracel (ZEVASKYNTM) 的开发和监管里程碑.
- 突显这种基于自身细胞的基因疗法的治疗潜力.
- 为了记录prademagene zamikeracel在RDEB患者中的首次批准.
主要方法:
- 开发一种基于细胞表的自身基因疗法.
- 对患者自身细胞进行基因改造,以引入 COL7A1 基因的功能副本.
- 在RDEB患者中用于伤口治疗的prademagene zamikeracel的临床评估
主要成果:
- 通过基因改造的自身细胞,Prademagene zamikeracel成功地传递了功能性的 COL7A1 基因拷贝.
- 在治疗与RDEB相关的慢性伤口方面已证明有效.
- 在成人和儿科RDEB患者的治疗中获得了监管批准.
结论:
- 在RDEB治疗中,Prademagene zamikeracel是一个显著的进步.
- 这种基因疗法通过针对遗传缺陷提供了一种新的治疗方法.
- 批准标志着提供RDEB疾病修饰疗法的里程碑.
更多相关视频
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
2.8K
11:36Rapid and Efficient Generation of Recombinant Human Pluripotent Stem Cells by Recombinase-mediated Cassette Exchange in the AAVS1 Locus
Published on: November 20, 2016
9.9K
相关概念视频
01:02Prescription, Nonprescription and Orphan Drugs
842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
01:19Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
01:30Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:23Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252